As the year comes to a close this week, it is a good time to look back on 2010 and consider the major events in the stem cell field and give out awards. Stem Cell Event of the Year. I would give this award as a dual prize to Geron and Advanced Cell Technology (ACT) […]
Stem Cell Awards for 2010 Read More »
I first published this a year ago, but with the 2012 election coming up, I think it is even more relevant today. In the debate over funding for embryonic stem cell research, it is usually assumed that Democrats are in favor of embryonic stem cell research and that Republicans are opposed. But recent polls suggest
Talking points about Stem Cells for Republicans Read More »
It happens several times a month these days. Some new, interesting paper comes out on IPS cells or on transdifferentiation. Immediately, opponents of ES cell research criminally twist the findings in the new paper and produce ‘news’ headlines that pop up high on Google to the effect that ES cells are now ‘obsolete’. IPS cells
Stem Cells and Cars Read More »
What is the best way to get new stem cell-based therapies to the millions of patients who need help? I would argue that this is the key question in the field of stem cell biology and regenerative medicine. Sometimes I think it is easy for folks to lose sight of that and fall into traps.
From Point A to Point Z: thinking outside the box about stem cells Read More »
It has been a rollercoaster few months between the anti-hESC court cases as well as Geron and Advanced Cell Technology (ACT) receiving the OK from the FDA to proceed with initial clinical trials of stem cell treatments. It’s OK to be excited about the clinical trials and I for one am, but we have to
Challenges translating stem cell treatments to patients Read More »
The FDA has given Advanced Cell Technology (ACT) the go ahead to begin their clinical trial using retinal progenitor cells derived from hESC by clearing the company’s IND application, bringing hope to those with vision loss and even blindness. The trial will be a combined Phase I/II to treat Stargardt’s Macular Dystrophy and has huge
The trouble with the risk of teratoma presents a stem cell paradox. Stem cells possess two traits lacking in other cells: self-renewal and pluripotency. This duo of defining functions is key to the ability of stem cells to be used to treat patients via regenerative medicine. A paradox exists because while self-renewal and pluripotency are both
The trouble with teratoma: a stem cell paradox Read More »
If IPS cells are not ready for prime time, it is probably due to these three critical challenges for these amazing cells. TUMORIGENICITY Those of us who work with IPS cells are very excited about their potential for use in regenerative medicine therapies. One serious hurdle we have talked about in the past is tumorigenicity.
Not ready for prime time: the three critical challenges for IPS cells Read More »
Cancer is a class of diseases that are intimately linked to stem cells. In fact, I would go so far as to call some types of cancer cells and stem cells, cousins. This concept, of a tight relationship between stem and cancer cells, is under intense investigation but at the same time it is something
Disease Focus Series: Cancer Read More »
It has been an eventful year so far for the stem cell field. Where do we go from here ? What are the key questions that face the field? Below are my top 10 questions for the field, NOT listed in any particular order, and some predictions. Update: you can see the predictions for the
Questions & my predictions for the stem cell field right now Read More »